Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Date:12/6/2011

ANAHEIM, Calif., Dec. 6, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the Oppenheimer Healthcare Conference to be held on December 13-14, 2011 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, December 13, 2011 at 2:45 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
3. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
4. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
9. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
10. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... working with highly-concentrated, opaque, or solid samples ... cells, polymer films, or phosphors, front-face fluorescence ... qualitative fluorescence measurements. Highly concentrated and opaque ... complete attenuation of the beam. When measuring ...
... , ... , Fluorescence immunoassay is applied ... stimulation. Interference from other sample components is limited by use ... The detection system includes a T-format sampling module mounting two ...
... By Laura Gaidar, Kristin Prasauckas, , ... , PerkinElmer Life Sciences, Inc. ... , AlphaScreen technology is ... high throughput screening applications. PerkinElmer Life Sciences has developed two instruments for ...
Cached Biology Technology:Immunoassay of Theophylline by fluorescence polarisation 2Immunoassay of Theophylline by fluorescence polarisation 3Immunoassay of Theophylline by fluorescence polarisation 4Immunoassay of Theophylline by fluorescence polarisation 5Immunoassay of Theophylline by fluorescence polarisation 6Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 2Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 3Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 4
(Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
(Date:4/23/2014)... date of the family of bacteria that causes ... and reveals surprising findings about the bacteria,s origin ... health strategies to control this respiratory disease, which ... analysis of 343 strains of the Bordetella ... over the last 100 years illustrates how vaccination ...
(Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
...   According to a new market research ... - 2015) ", published by,MarketsandMarkets ... reach $3656.8 million by,2015 at a CAGR of 27.6% and ... 2015 at a CAGR of 25.6% ...
... , Like the vast African plains, two huge expanses of ... an array of marine predators in predictable seasonal patterns, according ... of Pacific Predators (TOPP) project published today in the ... decade-long effort to track top marine predator movements in the ...
... in the North Sea will promote fish stock recovery and ... the University of York., In the North Sea up to ... caught, with the result that many fisheries are now badly ... the late 1980s and their fisheries are now some of ...
Cached Biology News:MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 2MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 3MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 4Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 2Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 3Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 4Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 5Discards ban 'will boost fisheries', says new research 2
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... imaging software for the microscopy market ... cameras, components and peripherals with powerful ... Its intuitive interface simplifies workflow and ... providing powerful features such as image ...
Biology Products: